Hafnium oxide radioenhancer NBTXR3
In the Act.In.Sarc phase 2–3 trial in locally advanced soft-tissue sarcoma, hafnium oxide nanoparticles (NBTXR3) injected into the tumour before radiotherapy doubled the pathological complete response rate, 16% versus 8% with radiotherapy alone.
Publisher update notice: erratum
Built / tested: NBTXR3
As reported in: Bonvalot, Rutkowski, Thariat et al. (2019). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. The Lancet Oncology. doi:10.1016/s1470-2045(19)30326-2